Who is sponsoring NCT04402892?

NCT04402892 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT04402892?

Interventions in NCT04402892: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ), 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients).

What condition does NCT04402892 study?

NCT04402892 studies COVID-19, SARS-CoV-2 Infection.

Is NCT04402892 still recruiting?

NCT04402892 is currently status unknown. Last updated 27 May 2020.

Last reviewed 2020-05-27 · How we verify

NCT04402892: MEMO-COV2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells

Status unknown NA Last updated 27 May 2020

What this trial tests

NA trial testing 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) in COVID-19 in 60 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 March 2021

1 March 2021

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	60
Start date	1 June 2020
Primary completion	1 March 2021
Estimated completion	1 March 2021

Drugs / interventions tested

35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )
35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with COVID-19 or SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current pandemic caused by the newly identified coronavirus responsible for COVID-19 is a major threat to our populations and societies. Hypothesis/Objective The acquisition of protective immunity at the level of the individual, either through vaccination or natural resolution of the infection, progressively leads at the level of the population to the reduction of the fraction of the population that can be productively infected and transmit the virus, hence, leading to the diminution of the rate of transmission, a phenomenon called herd immunity. Herd immunity was proposed as a strategy to control the infection. However, it remains difficult to model group immunity given the limited knowledge of the interaction between the host immune system with the virus, whose capacity to evolve in face of a neutralizing response is also not known. It is therefore important to acquire a better knowledge of the immunological memory that ensures the resolution of COVID-19 after SARS-CoV2 infection. Method To study single-cell B and T memory cells specific for the anti-SARS-CoV-2 response and characterize somatic mutations of immunoglobulin genes and TCR, in hospitalized and symptomatic patients and in patients cured of SARS-CoV-2.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
Sokal A, Chappert P, Barba-Spaeth G, Roeser A, et al · · 2021 · cited 306× · PMID 33571429 · DOI 10.1016/j.cell.2021.01.050
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants.
Sokal A, Barba-Spaeth G, Fernández I, Broketa M, et al · · 2021 · cited 128× · PMID 34614412 · DOI 10.1016/j.immuni.2021.09.011
Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.
Sokal A, Broketa M, Barba-Spaeth G, Meola A, et al · · 2022 · cited 46× · PMID 35483354 · DOI 10.1016/j.immuni.2022.04.002
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
Sokal A, Bastard P, Chappert P, Barba-Spaeth G, et al · · 2023 · cited 31× · PMID 36342455 · DOI 10.1084/jem.20220258
Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
Obi AT, Barnes GD, Napolitano LM, Henke PK, et al · · 2021 · cited 30× · PMID 32916371 · DOI 10.1016/j.jvsv.2020.08.030
Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.
Attias P, Azzaoui I, El Karoui K, de La Selle A, et al · · 2022 · cited 14× · PMID 35764393 · DOI 10.2215/cjn.00830122
COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches.
Zavvar M, Yahyapoor A, Baghdadi H, Zargaran S, et al · · 2022 · cited 13× · PMID 35248946 · DOI 10.1016/j.intimp.2022.108655
Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics.
Broketa M, Sokal A, Mor M, Canales-Herrerias P, et al · · 2023 · cited 6× · PMID 37252802 · DOI 10.1172/jci.insight.166602

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04402892 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 27 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04402892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing